An interventional study of Active Temporal Interference Stimulation (TIS) and Placebo / Sham TIS in Mild Cognitive Impairment (MCI) Amnestic, Lewy Body Disease With Mild Cognitive Impairment and Parkinson's Disease With Mild Cognitive Impairment, sponsored by Masaryk University. Recruiting at 1 site in Czechia. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Masaryk University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Cognitive Dysfunction with a site in Czechia — 10 open to participants now, 14 under way, 2 of them phase 3. Cognitive Dysfunction · Czechia.
Among the 36 studies in Cognitive Dysfunction with a site in Czechia, this one is the 16th largest by planned enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2026, is one of 18 with no phase, reaches primary completion later than 10 of the 13 other live ones, and was the 34th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →10 of the 36 studies in Cognitive Dysfunction with a site in Czechia are open now. Recruiting first, the newest first:
Tomas Bata Hospital, Czech Republic · Sites in Czechia
Ages 65+ · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Czechia, Australia, Austria and 14 more countries
Ages 18+
Masaryk University · Sites in Czechia
Ages 60–80 · Healthy volunteers
University of Ostrava · Sites in Czechia
Ages 50–80
Bristol-Myers Squibb · Sites in Czechia, United States, Argentina and 16 more countries
Ages 60–85
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 80 across the 30 interventional studies, 800 across the 6 observational. Of the 17 that completed or were terminated, 4 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
Masaryk University is the lead sponsor of 47 studies on the registry; 20 are open to participants now.
Masaryk University has 8 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
2 of the studies in Cognitive Dysfunction with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07042087St. Anne's University Hospital Brno, Czech RepublicLifestyle for the BRAin Health - Time Restricted Eating and Mindfulness | 2026-12 |
| NCT07757542University of OstravaSafety Assessment of H2 Inhalation in Patients With Mild Cognitive Impairment | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Cognitive Dysfunction with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the immediate effects of non-invasive temporal interference stimulation (TIS) targeting the striatum on sentence processing and brain connectivity in patients with neurodegenerative diseases.
The study aims to investigate the immediate effects of non-invasive temporal interference stimulation (TIS) targeting the deep structures of the fronto-striatal circuit involved in language processing. The research focuses on patients with neurodegenerative diseases who often suffer from communication deficits and impaired sentence comprehension.
Participants will undergo a cross-over design consisting of a single session of active TIS directed at the striatum and a session of placebo stimulation. The stimulation will be administered in a randomized order. The duration of the stimulation is approximately 20 minutes. During the stimulation, participants will perform a sentence comprehension task. Resting-state fMRI measurements will be taken before and after the stimulation to evaluate offline effects on brain connectivity and potential neuroplasticity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants first receive single-session active TIS targeting the striatum for approx. 20 minutes. Following a washout period, they receive placebo (sham) TIS.
Device: Active Temporal Interference Stimulation (TIS) · Device: Placebo / Sham TIS
Participants first receive single-session placebo (sham) TIS for approx. 20 minutes. Following a washout period, they receive active TIS targeting the striatum.
Device: Active Temporal Interference Stimulation (TIS) · Device: Placebo / Sham TIS
Non-invasive brain interference stimulation applied for approximately 20 minutes while the participant performs a sentence comprehension task.
Placebo stimulation applied for approximately 20 minutes while the participant performs a sentence comprehension task.
Changes in Task-Related Brain Activation
Assessment of the immediate offline effects of the prior stimulation on brain activation in language and fronto-striatal networks. This is measured using functional magnetic resonance imaging (fMRI) during an fMRI-adapted language task immediately after the stimulation session. The Blood Oxygen Level-Dependent (BOLD) signal acquired following active TIS will be compared to the signal acquired following placebo (sham) TIS.
Time frame: Immediately following the 20-minute stimulation session (approximately 0 to 30 minutes post-stimulation).
Changes in Resting-State Functional Connectivity
Evaluation of short-term neuroplasticity and network-level changes induced by the stimulation. Resting-state functional magnetic resonance imaging (rs-fMRI) data acquired immediately after the active TIS session will be compared to rs-fMRI data acquired after the placebo (sham) TIS session to identify changes in functional connectivity between the targeted striatum and broader cortical language networks.
Time frame: Immediately following the 20-minute stimulation session (approximately 0 to 30 minutes post-stimulation).
Behavioral Performance in Sentence Comprehension Task
Evaluation of language processing measured by accuracy (number or percentage of correct responses) and reaction time (in milliseconds) during the Sentence Comprehension Task. This task is completed by the participant concurrently with the administration of either active Temporal Interference Stimulation (TIS) or placebo (sham) TIS outside of the MRI scanner.
Time frame: During the approximately 20-minute stimulation intervention.
Plan to share: Yes — The study follows Open Science and FAIR data principles, adhering to the standard of 'as open as possible, as closed as necessary.' IPD, including neuroimaging and behavioral data collected at the CEITEC MAFIL laboratory, are considered sensitive personal data. Therefore, data will be strictly anonymized. Fully anonymized participant data will be made publicly available via trusted data repositories (such as Zenodo or Figshare) and assigned a persistent identifier (DOI). For any specific datasets where full anonymization is not possible due to the sensitive nature of the data and privacy protection regulations, the raw IPD will not be shared; instead, only the metadata will be published.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: The anonymized data will be stored and made available for a minimum of 5 years after the completion of the project.
Access criteria: Open access via repositories (Zenodo/Figshare) for fully anonymized data.
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Dec 2027, 21 months later.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 21 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Masaryk University